Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) released its quarterly earnings data on Tuesday. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.73) by $0.09, Bloomberg Earnings reports. The company had revenue of $3.84 million for the quarter. Sonoma Pharmaceuticals had a negative return on equity of 46.03% and a net margin of 60.58%.

Sonoma Pharmaceuticals (NASDAQ SNOA) traded down 13.74% during trading on Thursday, hitting $5.15. 58,708 shares of the stock were exchanged. The stock has a 50 day moving average of $6.78 and a 200-day moving average of $6.82. The stock has a market cap of $22.15 million, a P/E ratio of 2.35 and a beta of 1.30. Sonoma Pharmaceuticals has a 52 week low of $3.62 and a 52 week high of $8.25.

WARNING: This piece of content was reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/08/10/sonoma-pharmaceuticals-inc-nasdaqsnoa-posts-earnings-results-misses-estimates-by-0-09-eps.html.

Separately, Maxim Group reissued a “buy” rating and set a $10.00 price objective (up previously from $9.00) on shares of Sonoma Pharmaceuticals in a research report on Tuesday, June 6th.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.

Earnings History for Sonoma Pharmaceuticals (NASDAQ:SNOA)

Receive News & Ratings for Sonoma Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.